Clinico-pathological study of superficial bladder cancer (pTa/pT1) informs about prognostic factors such as the size of the tumor, its uni or multifocal character, its grade and stage. Presently, these factors constitute the basis of therapeutic decision but do not allow to foresee the prognosis with certainty. Many technics have contributed to a better knowledge of such tumors; however, they have not allowed to fully master prognostic uncertainties. During the last decades, cell cycle and DNA content study by flow cytometry has been developping, bringing an additional prognostic element to various types of tumors. We have decided to study the impact of this technique to the assessment of the prognosis of superficial bladder tumors. The study concerned 65 patients presenting superficial bladder tumors (pTa/ pT1), with a follow-up of at least two years in case of not recurrence and in case of recurrence, having had a second resection with analysis of sections. Flow cytometry was applied to formol-fixed and paraffin-embedded endoscopic resection material of initial tumors by simple-labelling of DNA with propidium iodide. Following cytometric study, 35 (54%) of tumors were aneuploid and 30 (46 %) were diploid. For the diploid ones, S-phase mean value was 14.94% (from 2.72% to 33.43%); and G2M mean value was 8.3 (from 1% to 18%). The presence of an DNA- aneuploid peak had a predictive value of recurrence and progression in stage, with relative risks of 12 and 6.85 respectively. It was also correlated with the histological grade and stage. On the other hand, S-phase and G2M values had no prognostic significance.

During malignant transformation, cells accumulate genetic and epigenetic alterations. Since ten years, the knowledge of the whole human genome, associated with the development of new molecular biology techniques allowing global analysis, encouraged the identification of these anomalies. Thus, transcriptome studies with DNA chips allowed the characterization of genes groups whose expressions vary according to the type of tumors or according to their recurrence. We analysed adrenal tumors with DNA chips and tried to characterize recurring carcinomas. On the other hand, tumor suppressor genes expression could be inhibited by epigenetic modifications like gene promoter hypermethylation. With development of sensitive methods like PCR, methylation profile could be defined. We were interested in lung and head and neck tumors and tried to evaluate if the presence of methylated gene in bronchial lavage or in saliva could be a good marker for the early detection of a primary tumor or of a recurrence.

Brooke Spiegler syndrome is a rare genodermatosis characterized by an association of multiple trichoepitheliomas and cylindromas, sometimes accompanied by other adnexal tumors (spiradenoma, mila), we report two family cases of Brooke Spiegler syndrome. In the first case: a 31 years-old woman, with multiple trichoepitheliomas involving in the naso-genal areas, with multiple cylindromas of the scalp. The second case regarding the brother: 37 years-old, presented with multiple trichoepitheliomas of the face, associated with milia. No neoplastic tumor was identified. A co-existence of adnexal tumors was found in the other members of the family. Brooke Spiegler syndrome is an autosomial dominant disease with variable penetrance, it's characterized by a family history of trichoepitheliomas, with other adnexal tumors. The course of the disease is characterized by a multiplication of lesions, a malignant transformation was reported, but remains rare. Brooke Spiegler syndrome is usually a benign disease, but patients with this syndrome should be explored for malignancy. A family study is indicated.

Five percent of breast cancers are associated with a genetic predisposition, transmitted as an autosomal dominant trait of either maternal or paternal origin. Mutations of the BRCA1 or BRCA2 genes are associated with a high risk of breast and ovarian cancer and depend in part on these predispositions. The objectives of an oncogenetic consultation are to understand the origin of a personal and family history of breast cancer by using the resources of formal and molecular genetics and to guide the management of the consulting patient and her relatives. The diagnostic genetic test performed from an "index case" is intended to identify genetic alterations specific to each family. The failure to identify a mutation in a diagnostic test does not rule out the existence of a predisposing factor. On the other hand, the identification of a mutation makes it possible to offer a simple test to relatives, and its negative result can provide reassurance. Optimal management of patients with a mutation of the BRCA1 or BRCA2 genes requires frequent clinical examinations and at least annual imaging (mammography, ultrasound or breast MRI as part of a protocol) from the age of 25-30 years. Prophylactic mastectomy may be envisioned. Prophylactic adnexectomy is also usually recommended to prevent ovarian cancer, around the age of 40 years.

Since 1940, the evolution in analysis and treatment of bladder cancer refines our staging systems and enhances our capabilities in assessing a diagnosis, a prognosis and in defining appropriate treatments. Such a study implies a critical conceptualisation of tumour developmental pathways, added by the recent observations in molecular biology research.

The molecular mechanisms involved in liver carcinogenesis are poorly understood. Over the past decade, epigenetic changes (DNA methylation) have received increasing attention for their potential involvement in the development of hepatocarcinoma. The DNA methylation level is influenced by environmental factors (folate and methionine diet), as well as by genetic factors (methylenetetrahydrofolate reductase/MTHFR polymorphisms). These findings provide new insight into the understanding of liver carcinogenesis. Interventional studies are now required to determine the role of folate supplementation in the development of liver tumors in targeted patients.

More than 99.9 % of the sequence is identical when comparing the DNA from two individuals. The remaining 0.1 % is responsible, along with other factors such as the environment, for the risk level of developing complex diseases (such as asthma, diabetes or cancer) or for the different pharmacological response to drugs. Despite the incredible advances in genomics in the past few years, identifying the variants involved remains difficult because of the prodigious amount of information to process. The recent completion of the Haplotype Map of the human genome has raised great hopes in the field as it is expected to help reduce the complexity of association studies and thus accelerate the discovery of genes associated with complex diseases. This review details the rationale behind the HapMap project, gives a summary of the results and also describes potential applications of the Haplotype Map.

From differential analysis to identify biomarkers, to functional analysis for finding new therapeutic targets, proteomics bring new comprehensive information for a better understanding of the molecular basis of oncology and new perspectives for the clinic. However the major limitation of proteomic investigations, more generally of post-genomic approaches, remains the molecular and cellular complexity of the mammary gland that is still a major challenge.

The white sponge naevus is a rare benign, hereditary autosomal dominant disorder of the mucosa. The oral mucosa is most often affected, but vaginal and anal mucosal surfaces may also be involved. Clinically, a whitish-grey, ragged, and folded surface that has no clear demarcation and appears sponge-like is characteristic, often creating problems in differential diagnosis. A potential risk for malignant transformation of white sponge naevus lesions has not been reported. The therapy for this benign hereditary disorder is unknown, however does not appear to be necessary. In the present report of a family with known white sponge naevus in three different generations, clinical, histopathologic, cytopathologic, DNA-cytomertric, and genetic aspects are described and discussed.

Molecular markers can be used for the diagnostic (early detection, assessment of tumor extent, detection of residual disease), for the prognostic (disease classification and therapeutic indications), for the treatment (treatment target and predictive factors of tumor response to treatment) and for the prevention (identification of the at-risk population and chemoprevention). Molecular markers have to be validated by prospective studies using appropriate methods. Currently, no molecular marker is used in routine practice for the management of upper aerodigestive tract cancers, but new techniques are being developed to analyze simultaneously tens of thousands of markers; they should expand our knowledge of the biology of these cancers.

Calcium homeostasis of the endoplasmic reticulum (ER) is involved in intracellular signaling pathways and is implicated in major cell functions such as cell growth, differentiation, protein synthesis and apoptosis. The accumulation of calcium in the ER is performed by specific sarco/endoplasmic reticulum calcium transport ATPases (SERCA iso-enzymes). The expression of biochemically distinct SERCA isoforms is cell type dependent and developmentally regulated. This review summarizes pertinent data about the modulation of the expression of SERCA enzymes during the differentiation of normal and tumor cells. These data support the implication of SERCA pumps and especially SERCA3 in the differentiation program of cancer and leukemia cells. During the multi-step process of colon carcinogenesis, the decrease of SERCA3 expression seems to be linked to enhanced APC/ss-catenin/TCF4 signaling and deficient Sp1-like factor-dependent transcription.

Cancer is a complex and dynamic process caused by a cellular dysfunction leading to a whole organ or even organism vital perturbation. To better understand this process, we need to study each one of the levels involved, which allows the scale change, and to integrate this knowledge. A matricellular protein, PAI-1, is able to induce in vitro cell behaviour modifications, morphological changes, and to promote cell migration. PAI-1 influences the mesenchymo-amaeboid transition. This matricellular protein should be considered as a potential 'launcher' of the metastatic process acting at the molecular, cellular, tissular levels and, as a consequence, at the organism's level.